Drug Profile
Immunotherapeutics companion diagnostic - ImmunID
Alternative Names: ImmunIG®; ImmunTraCkeR®; Ipilimumab companion diagnostic - ImmunID; SCIB 1 companion diagnostic - ImmunIDLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator ImmunID
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Diagnosis, Metastatic disease) in France
- 23 Feb 2016 ImmunID and the Memorial Sloan Kettering Cancer Center agree to co-develop ipilimumab companion diagnostic for Solid tumours
- 15 Feb 2016 ImmunTraCkeR® receives CE mark approval in Europe